Erythema multiforme following vaccination for <scp>SARS‐CoV</scp>‐2: Report of a case and review of the literature − Secondary Publication

Kobayashi, Yuki; Adachi, Takeya; Arakawa, Hiroki; Takeuchi, Mie; Inazumi, Toyoko

doi:10.1111/ajd.13917

Cited by 4 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 164 non‐injection‐site reactions in 161 patients have been reported in previous case reports and series 7–88 . Patients with systemic lupus erythematosus (SLE) and lupus erythematosus profundus (LEP) showed exacerbation of lupus eruptions after 2 weeks, and other AEs developed several months later.…”

Section: Resultsmentioning

confidence: 99%

Cutaneous adverse events following COVID‐19 vaccination: A case series of 30 Japanese patients and a review of 93 Japanese studies

Baba,

Yamada,

Kanekura

2024

The Journal of Dermatology

View full text Add to dashboard Cite

In Japan, cutaneous adverse events (AEs) following the coronavirus disease 2019 (COVID‐19) vaccination have been frequently described; however, a larger case series and literature review are lacking. There is an urgent need for an extensive investigation of new cases and previous reports to provide a thorough body of information about post‐COVID‐19 immunization cutaneous AEs. We aimed to analyze patients with cutaneous AEs after COVID‐19 vaccination in our hospital and review previous studies of cutaneous AEs. We analyzed post‐COVID‐19 vaccination cutaneous AEs in our department, the Japanese Registry, and previous literature. We enrolled 30 patients with cutaneous post‐vaccination AEs in our department over 2 years (April 1, 2021, to March 31, 2023). We also confirmed cases registered in the Ministry of Health, Labor, and Welfare COVID‐19 vaccine side effect reporting system (February 17, 2021–March 12, 2023). A total of 587 records were retrieved and 93 articles were included for data extraction. A total of 28 non‐injection‐site cutaneous AEs and two injection‐site AEs were identified. Six (20.0%) patients developed new‐onset erythematous eruptions, and five (16.7%) patients developed urticaria. Pruritic eruption, eczema, shingles, and sweating symptoms have also been reported. In previous studies on non‐injection‐site cutaneous AEs, individuals who received the BNT162b2 vaccine were older than those who received mRNA‐1273 (P < 0.01). Cutaneous AEs were mostly nonsignificant and self‐limiting reactions; however, rare, severe, or life‐threatening AEs were also reported. Physicians should be aware of the various possible cutaneous AEs associated with the COVID‐19 vaccination.

show abstract

Section: Resultsmentioning

confidence: 99%

Cutaneous adverse events following COVID‐19 vaccination: A case series of 30 Japanese patients and a review of 93 Japanese studies

Baba,

Yamada,

Kanekura

2024

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…These cases comprise newly developed lesions and flare-ups of pre-existing inflammatory dermatoses, categorised as Th1-polarised cutaneous inflammations [3] . Previous reports have shown that all cases of EM induced by a COVID-19 vaccine, excluding cases with an unknown prognosis, improved with topical steroids and oral antihistamines treatment [4] . In the present case, skin lesions developed 7 d after the second vaccination, persisted for more than 14 (11 + 3) weeks, and completely disappeared within 3 weeks after thymectomy.…”

mentioning

confidence: 96%

Letter re: SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis

Baba

Tokunaga

Sakasegawa

et al. 2023

European Journal of Cancer

View full text Add to dashboard Cite

Tozinameran

2023

Reactions Weekly

View full text Add to dashboard Cite

Erythema multiforme following vaccination for SARS‐CoV‐2: Report of a case and review of the literature − Secondary Publication

Cited by 4 publications

References 4 publications

Cutaneous adverse events following COVID‐19 vaccination: A case series of 30 Japanese patients and a review of 93 Japanese studies

Cutaneous adverse events following COVID‐19 vaccination: A case series of 30 Japanese patients and a review of 93 Japanese studies

Letter re: SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis

Tozinameran

Contact Info

Product

Resources

About